Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14681648 | 0.88 | SMN1; SMN2 (0.54) | RECQLUSP2SMN1; SMN2THRBGPR119 | |
| SCHEMBL78659 | 0.88 | HPGD (0.52) | RECQLUSP2SMN1; SMN2GPR119HPGD | |
| SCHEMBL78365 | 0.87 | HPGD (0.55) | RECQLUSP2SMN1; SMN2GPR119HPGD | |
| SCHEMBL2154252 | 0.85 | RECQL (0.49) | RECQLUSP2SMN1; SMN2THRBPRMT5 | |
| SCHEMBL2154251 | 0.85 | RECQL (0.49) | RECQLUSP2SMN1; SMN2THRBPRMT5 | |
| SCHEMBL6157453 | 0.83 | USP2 (0.60) | RECQLUSP2SMN1; SMN2THRBGPR119 | |
| SCHEMBL17275941 | 0.82 | RECQL (0.61) | RECQLUSP2SMN1; SMN2THRBGPR119 | |
| SCHEMBL16293179 | 0.82 | RECQL (0.54) | RECQLUSP2SMN1; SMN2THRBGPR119 | |
| SCHEMBL15353080 | 0.82 | SMN1; SMN2 (0.72) | RECQLUSP2SMN1; SMN2THRBMAPT | |
| SCHEMBL14681442 | 0.81 | SMN1; SMN2 (0.51) | RECQLUSP2SMN1; SMN2PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| WO-2013160810-A2 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013160810-A2 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2013-10-31 | — | — | WO | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2231638-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | BET1, PGGT1B, RABGGTB | RECQL 3450/4885USP2 4451/4885SMN1; SMN2 4819/4885 |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | RECQL 1114/4885USP2 4469/4885SMN1; SMN2 3505/4885 |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | RECQL 1114/4885USP2 4469/4885SMN1; SMN2 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.